NCT07711158尚未招募2 期
An Open-Label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of SR604 Injection in Patients With Congenital Coagulation Factor VII Deficiency
Shanghai RAAS Blood Products Co., Ltd.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Treated overall Annualized Bleeding Rate (ABR)
研究概览
简要总结
This is an open-label, multicenter, exploratory Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of SR604 Injection in patients with congenital coagulation Factor VII deficiency.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥12 years and ≤65 years at the time of signing the informed consent form; both genders eligible;
- •Clinically diagnosed with congenital coagulation Factor VII deficiency, with historical or screening FVII activity <10%, and ≥2 treated new-onset bleeding events within 3 months prior to enrollment;
- •No active bleeding symptoms prior to first administration of SR604 Injection;
- •The subject and/or legal representative and impartial witness have signed the informed consent form, indicating voluntary agreement to participate in this trial, to provide biological samples for testing as required by the protocol, and to comply with the planned study visits;
- •Female subjects (post-menarche) must have a negative serum pregnancy test (HCG) during the screening period; subjects with childbearing potential (females post-menarche or males post-spermarche) must agree to use highly effective contraceptive measures throughout the study period.
排除标准
- •Known history of hypersensitivity to the study drug formulation or any of its components;
- •Intolerance to subcutaneous injection or other local skin abnormalities or dermatoses that may affect drug administration or safety assessment;
- •Meeting any one of the following criteria during screening:
- •Hemoglobin <60 g/L;
- •Platelet count <100×10⁹/L;
- •Abnormal hepatic or renal function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.5× upper limit of normal (ULN), or total bilirubin ≥1.5× ULN; or serum creatinine (Cr) ≥1.5× ULN;
- •Positive for anti-human immunodeficiency virus (HIV) antibodies.
- •Any bleeding disorder other than congenital Factor VII deficiency, or other conditions causing significantly abnormal coagulation parameters (e.g., hemophilia A or B, von Willebrand disease, platelet disorders, vitamin K deficiency, etc.);
- •Protein C deficiency or Protein S deficiency;
- •History of thrombosis, family history of thrombosis, or history of thrombophilia;
- •Intracranial hemorrhage within 2 years prior to signing the informed consent form;
- •Severe cardiac disease, such as unstable angina, congestive heart failure (New York Heart Association class ≥III), serious arrhythmia (QTc interval >450 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), etc.;
- •Female patients with menstrual abnormalities caused by organic gynecological conditions (e.g., uterine fibroids, endometriosis, adenomyosis, etc.);
- •Received Factor VII-containing products within 48 hours prior to first administration of SR604 Injection; received whole blood or plasma transfusion within 2 weeks prior to first administration of SR604 Injection;
- •Used any anticoagulants, antifibrinolytics, or agents affecting platelet function (including chemical drugs, biological products, or traditional Chinese medicine), including aspirin, within 1 week prior to screening, or required use of such agents during the treatment period;
- •Underwent major surgery (defined as Grade III or IV surgery) within 1 month prior to signing the informed consent form, or planned to undergo surgery during the study period;
- •Enrolled in other clinical trials within 1 month prior to signing the informed consent form;
- •Miscarriage or pregnancy termination within 3 months prior to signing the informed consent form; pregnant or breastfeeding women;
- •Mental illness or significant psychiatric disorder, or incapacity or lack of cognitive ability due to other causes;
- •Other conditions deemed by the investigator to be unsuitable for enrollment, such as alcoholism, anticipated poor subject compliance preventing completion of dosing and study follow-up, poorly controlled comorbid chronic diseases, or serious systemic diseases.
结局指标
主要结局
Treated overall Annualized Bleeding Rate (ABR)
时间窗: Through 28 weeks of treatment.
次要结局
- Treated spontaneous annualized bleeding rate(over 28 weeks of treatment)
- Treated overall annualized joint bleeding rate(over 28 weeks of treatment)
- Annualized menorrhagia bleeding rate (menstruating females only)(over 28 weeks of treatment)
- Overall annualized bleeding rate including treated and untreated bleeding events(over 28 weeks of treatment,)
- Change in PBAC score (menstruating females only);(From baseline over 28 weeks of treatment)
- Change in EQ-5D-5L health index score(From pre-treatment over 28 weeks of treatment)
- Change in EQ-VAS score(From baseline over 28 weeks of treatment;)
- Subject overall satisfaction score with treatment efficacy(over 28 weeks of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial HypercholesterolemiaNCT07591298CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.18
已完成
2/3 期
A Randomized, Open label, Multicenter, Phase II / III study to assess and compare the immunogenicity and safety of NUCOVAC®-11CTRI/2025/02/081007PANACEA BIOTEC LIMITED446
招募中
2 期
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideNCT07454837Mirum Pharmaceuticals, Inc.120
尚未招募
2 期
A Phase 2 Study of HW211026Actinic KeratosisNCT07513454Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.80
招募中
2 期
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLCNCT07398937Fudan University116